OTCMKTS:GNWSF StageZero Life Sciences (GNWSF) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free GNWSF Stock Alerts $0.04 +0.01 (+33.33%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$0.03▼$0.0450-Day Range$0.03▼$0.0452-Week Range$0.00▼$1.27Volume15,640 shsAverage Volume26,719 shsMarket Capitalization$2.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get StageZero Life Sciences alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About StageZero Life Sciences Stock (OTCMKTS:GNWSF)StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.Read More GNWSF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNWSF Stock News HeadlinesApril 20, 2024 | msn.comCommunity invited to learn about the life sciences, meet industry leaders, and tour facilities at Momentum LabsApril 19, 2024 | bizjournals.comNew report shows sustained growth for Washington's life science industryApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 4, 2024 | theglobeandmail.comStageZero Life Sciences: Top 10 Undervalued Healthcare Sector Stocks on TSX (SZLS)March 5, 2024 | msn.comLife Below Zero Season 9 Streaming: Watch & Stream Online via Disney PlusFebruary 15, 2024 | bizjournals.comWu awards $4.7 million to train Bostonians in life sciences industryFebruary 3, 2024 | msn.comWhat Is the Sandwich Generation? Here’s What You Need to Know About This Growing CohortNovember 15, 2023 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational UpdateApril 25, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.October 26, 2023 | bizjournals.comIn life sciences, Boston continues to reign supremeOctober 5, 2023 | bizjournals.comNew York City life-science market ranks among top 10 in countryOctober 3, 2023 | bizjournals.comSyneos Health replaces CEO with life sciences veteran Colin Shannon days after $7B deal closesSeptember 12, 2023 | markets.businessinsider.comSustainability, equipment upgrades, and digitalization: big priorities for global pharmaceuticals, life science global study findsSeptember 11, 2023 | msn.comReport: Mass. life sciences grew in 'toughest times' in Worcester, Suffolk countiesJune 29, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - SZLS.WTJune 20, 2023 | finance.yahoo.comStageZero Life Sciences, Ltd. Announces Temporary Repricing of Warrants Expiring in 2023 and 2024June 5, 2023 | finance.yahoo.comStageZero Life Sciences, Ltd. Special and Annual General Meeting Conference CallMay 29, 2023 | msn.com5 innovators to watch in R.I.’s life sciences industryMay 16, 2023 | msn.comStageZero Life Sciences Ltd. GAAP EPS of -$0.02, revenue of $0.8MMay 12, 2023 | technews.tmcnet.comLife Science Instrumentation Market worth $73.9 billion | MarketsandMarketsApril 6, 2023 | bizjournals.comDemand outstripping construction in L.A.'s life-science real estate marketMarch 31, 2023 | finance.yahoo.comStageZero Life Sciences, Ltd Announces Q4 2022 and Year End Financial Results and Operational UpdateJanuary 25, 2023 | forbes.comIt's Time For The Life Sciences Industry To Embrace Quality 4.0January 17, 2023 | nytimes.comWhat Happened to All of Science’s Big Breakthroughs?December 10, 2022 | theglobeandmail.comStageZero Life Sciences: Bottom 25 Performing Stocks Year-to-Date on TSX (SZLS)August 18, 2022 | finance.yahoo.comStageZero Life Sciences Announces Closing of Convertible Debenture FinancingAugust 17, 2022 | finanznachrichten.deStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q2 2022 Financial Results and Operational UpdateSee More Headlines Receive GNWSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for StageZero Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic Substances Sub-IndustryN/A Current SymbolOTCMKTS:GNWSF CUSIPN/A CIK1454263 Webwww.stagezerolifesciences.com Phone905-209-2030FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,860,000.00 Net Margins-200.26% Pretax MarginN/A Return on EquityN/A Return on Assets-165.13% Debt Debt-to-Equity RatioN/A Current Ratio1.15 Quick Ratio1.08 Sales & Book Value Annual Sales$4.15 million Price / Sales0.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-2.00Miscellaneous Outstanding Shares62,995,000Free FloatN/AMarket Cap$2.52 million OptionableNot Optionable Beta0.28 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. James R. Howard-TrippExec. Chairman & CEOMr. Carl SolomonInterim Chief Financial OfficerProf. Choong-Chin LiewCo-FounderMr. Warren Whitehead C.M.A. (Age 69)Chief Accountant Mr. David SuriaSr. ScientistKey CompetitorsStageZero Life SciencesOTCMKTS:SZLSFNavidea BiopharmaceuticalsNYSE:NAVBVirax Biolabs GroupNASDAQ:VRAXMyMD PharmaceuticalsNASDAQ:MYMDNemaura MedicalNASDAQ:NMRDView All Competitors GNWSF Stock Analysis - Frequently Asked Questions How have GNWSF shares performed in 2024? StageZero Life Sciences' stock was trading at $0.0294 on January 1st, 2024. Since then, GNWSF shares have increased by 36.1% and is now trading at $0.04. View the best growth stocks for 2024 here. How do I buy shares of StageZero Life Sciences? Shares of GNWSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:GNWSF) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding StageZero Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
